RT Journal Article SR Electronic T1 Investigating the role of common cis-regulatory variants in modifying penetrance of putatively damaging, inherited variants in severe neurodevelopmental disorders JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2023.04.20.23288860 DO 10.1101/2023.04.20.23288860 A1 Wigdor, Emilie M. A1 Samocha, Kaitlin E. A1 Eberhardt, Ruth Y. A1 Chundru, V. Kartik A1 Firth, Helen V. A1 Wright, Caroline F. A1 Hurles, Matthew E. A1 Martin, Hilary C. YR 2023 UL http://medrxiv.org/content/early/2023/04/25/2023.04.20.23288860.abstract AB Recent work has revealed an important role for rare, incompletely penetrant inherited coding variants in neurodevelopmental disorders (NDDs). Additionally, we have previously shown that common variants contribute to risk for rare NDDs. Here, we investigate whether common variants exert their effects by modifying gene expression, using multi-cis-expression quantitative trait loci (cis-eQTL) prediction models. We first performed a transcriptome-wide association study for NDDs using 6,987 probands from the Deciphering Developmental Disorders (DDD) study and 9,720 controls, and found one gene, RAB2A, that passed multiple testing correction (p = 6.7×10−7). We then investigated whether cis-eQTLs modify the penetrance of putatively damaging, rare coding variants inherited by NDD probands from their unaffected parents in a set of 1,700 trios. We found no evidence that unaffected parents transmitting putatively damaging coding variants had higher genetically-predicted expression of the variant-harboring gene than their child. In probands carrying putatively damaging variants in constrained genes, the genetically-predicted expression of these genes in blood was lower than in controls (p = 2.7×10−3). However, results for proband-control comparisons were inconsistent across different sets of genes, variant filters and tissues. We find limited evidence that common cis-eQTLs modify penetrance of rare coding variants in a large cohort of NDD probands.Competing Interest StatementH.V.F. is an author of Oxford Desk Reference: Clinical Genetics & Genomics. M.E.H. is a consultant for AstraZeneca, and is a non-executive director of, consultant to, and holds shares in Congenica.Funding StatementThe DDD study presents independent research commissioned by the Health Innovation Challenge Fund (grant number HICF-1009-003), a parallel funding partnership between Wellcome and the Department of Health, and the Wellcome Sanger Institute (grant number WT098051). This study makes use of DECIPHER, which is funded by the Wellcome Trust. The full acknowledgements can be found at www.ddduk.org/access.html. Sanger investigators are currently funded by Wellcome grant 220540/Z/20/A. We used data from UKHLS, which is led by the Institute for Social and Economic Research at the University of Essex and funded by the Economic and Social Research Council (grant number ES/M008592/1). The data were collected by NatCen.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The DDD study has UK Research Ethics Committee approval (10/H0305/83, granted by the Cambridge South REC, and GEN/284/12 granted by the Republic of Ireland REC.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe DDD data are available in the European Genome-Phenome Archive (EGA). These include the exome sequence data (EGAD00001004389), phenotypic and family descriptions (EGAD00001004388), CoreExome array data (EGAD00010001598, EGAD00010001600, EGAD00010001604) and Global Screening Array data (EGA upload in progress, dataset numbers to be confirmed). The UKHLS genotype data are also available on EGA (EGAS00001001232).